Abstract
PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have